To investigate the bioavailability and bioequivalence of three formulations of eslicarbazepine acetate: 50 mg/mL oral suspension (Test 1), 200 mg tablets (Test 2) and 800 mg tablets (Reference) ; AES Proceedings of the Annual Meeting of the American Epilepsy Society
To investigate the bioavailability and bioequivalence of three formulations of eslicarbazepine acetate: 50 mg/mL oral suspension (Test 1), 200 mg tablets (Test 2) and 800 mg tablets (Reference) ; AES Proceedings of the Annual Meeting of the American Epilepsy Society
Financiadores do RCAAP | |||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |